Disclosures for "Evidence-sharing Methods Utilized by Clinicians During Prognostication Meetings for Critically Ill Neurologic Patients"
-
Ms. Kotamreddy has nothing to disclose.
-
Ms. Honzel has nothing to disclose.
-
Dr. Carandang has nothing to disclose.
-
Dr. Muehlschlegel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma Inc.. Dr. Muehlschlegel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acasti Pharma Inc.. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of an immediate family member of Dr. Muehlschlegel has received research support from NIH. Dr. Muehlschlegel has a non-compensated relationship as a Member of Board of Directors with Neurocritical Care Society that is relevant to AAN interests or activities.